X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

Content Team by Content Team
14th February 2022
in Packaging & Logistic, Press Statements
Envirotainer introduces the RAP for the future - part of the Releye series

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, launched its latest innovation, the Releye® RAP. This is complemented by the new Control Tower managed service.

The Releye® RAP sets a new benchmark for temperature-controlled 5-pallet solutions. The largest of the new generation Releye® containers, the RAP is the only one of its type in the world, combining big capacity with superior features.

Designed to meet the strictest requirements in pharmaceutical air freight, the integrated live monitoring enables a unique insight into product condition, location and progress of the shipment.

With its increased efficiency and capacity, it reaches outstanding CO2 reductions per shipment, and is the future solution for secure cold chain shipments. All monitored and maintained with the new service Control Tower.

The Releye® RAP is the second in a family of advanced temperature-controlled air freight containers Envirotainer is developing. It joins the 3-pallet Releye® RLP launched in 2021. The foundation of the Releye® platform are the five pillars: Control, Monitoring, Autonomy, Value and Sustainability.

More Value, More Sustainability

Because the Releye® RAP offers the largest internal volume for temperature-controlled air freight shipments, it makes more efficient use of available air cargo capacity. This offers the best value Total Landed Cost and achieves the lowest CO2 footprint in the air cargo industry.

Quite simply, it offers the most cargo space per fuel unit and has the smallest CO2 footprint of all solutions on the market. This is thanks to its low weight, large cargo space and outstanding reliability.
Easy Qualification?

The beauty of the Releye® RAP is that it is based on exactly the same platform and technology as the Releye® RLP. Thanks to this and the comprehensive data made available, the additional qualification of a Releye® unit is the easiest in the cold chain industry and requires marginal effort from our customers and partners.

Control Tower

The Envirotainer Control Tower service offers a global team of operators to follow a shipment’s every move, ready to respond within minutes to any critical event. The Envirotainer Control Tower service is included with all Releye® leases.

Swiss WorldCargo, the leading carrier in intensive care pharmaceutical shipments, is the first European carrier to approve the Releye® RAP container for their operations and to add it to their portfolio.

“We really appreciate our close partnership with Envirotainer and are proud to be the first European carrier to approve the new Envirotainer Releye® RAP and to welcoming it into our product portfolio,” said Lorenzo Stoll, Head of Cargo at Swiss International Air Lines. “The Releye® RAP sets a new benchmark for temperature-controlled 5-pallet solutions, it combines newest technology and reaches outstanding CO2 reductions per shipment. This fully aligns with our own focus on sustainable operations and continued reduction of our carbon footprint.”

“When we launched the new Releye® RLP in May 2021, we raised the bar in cold chain transportation to new heights of Control, Monitoring and Autonomy. Now, with the launch of Releye® RAP, we raise the bar yet another notch in terms of Value and Sustainability”, says Peter Gisel-Ekdahl, CEO at Envirotainer.

“The COVID-19 pandemic is ongoing. Air cargo capacity is constrained and there’s a huge demand for intercontinental shipments. In this context, organisations that qualify the Releye® RAP will secure access to the most cost-efficient and sustainable solution for temperature-controlled airfreight,” says Fredrik Linnér, Chief Business Development Officer at Envirotainer.

“The Releye® series offer unique visibility, and with the Control Tower service, we’re taking visibility to another level. Based on the most sophisticated Live Monitoring technology in the market, and our 24/7/365 customer service, we are monitoring all Releye® shipments, offering our customers a helping hand within 15 minutes from any potential event happening, in order to secure the safe delivery of pharmaceuticals,” says Linus Wollentz, Head of Digital Services at Envirotainer

About Envirotainer

Envirotainer is the undisputed global market leader in secure cold chain solutions?for air transport of pharmaceuticals. The company develops, manufactures and offers leasing of innovative container solutions, including validation, support and service, for pharma products that require a controlled environment. Thanks to a truly global presence with the world’s largest active container fleet, the most extensive network and more than 35 years of industry expertise, Envirotainer is able to meet the customers’ need for innovative and reliable solutions – available from any location to any destination. The company operates through an open, global network of airlines and forwarders and the headquarters is located outside of Stockholm, Sweden.

Previous Post

Opticooler receives technical approval by Japanese major airlines

Next Post

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
Future Trends Shaping
Packaging & Logistic

Future Trends Shaping Pharma Supply Chain and Logistics

30th July 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Next Post
NIH begins study of allergic reactions to Covid-19 vaccines

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In